Pancreatic cancer (PC) remains one of the most challenging diseases, with a very poor 5-year overall survival of around 11.5%. Kirsten rat sarcoma virus (KRAS) mutation is seen in 90%-95% of PC patients and plays an important role in cancer cell proliferation, differentiation, metabolism, and survival, making it an essential mutation for targeted therapy. Despite extensive efforts in studying this oncogene, there has been little success in finding a drug to target this pathway, labelling it for decades as "undruggable". In this article we summarize some of the efforts made to target the KRAS pathway in PC, discuss the challenges, and shed light on promising clinical trials.
Keywords: Clustered regularly interspaced short palindromic repeats; Drug resistance; Kirsten rat sarcoma virus; Next generation sequencing; Pancreatic cancer; Targeted therapy.
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.